Concepedia

Author

Edwina N. Scott

University of Leicester

Also Known As

E SCOTT, E Scott, E. Scott, Edwina N Scott, Edwina N. Scott, Edwina Scott, Elizabeth F. Scott, Emma Adine Hoxer Scott

30

Publications

1.4K

Citations

11

H-Index

16

Concepts

All Affiliations

University of LeicesterUniversity Hospitals of Leicester NHS TrustRoyal Marsden HospitalLeicester Royal InfirmaryLawrence Livermore National Laboratory
EN

About

Edwina N. Scott is an author at University of Leicester specializing in oncology, cancer therapeutics, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

387

2

Pharmacology

4

4

387

3

Health Sciences

1

1

24

4

Cell Biology

1

1

175

5

Pathology

1

1

154

Edwina N. Scott

×

7

Publications

550

Citations

7

H-Index

YearCitations

Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice

Hong Cai, Edwina N. Scott, Abeer Othman A. Kholghi,

Science Translational Medicine

2015

175

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

Jens Samol, Malcolm Ranson, Edwina N. Scott,

Investigational New Drugs

2011

154

Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability

Glen R.B. Irving, Lynne Howells, Stewart Sale,

Cancer Prevention Research

2012

109

Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma

Edwina N. Scott, Giuseppe Garcea, H. Doucas,

HPB

2009

40

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

Edwina N. Scott, Anne Thomas, L Rhoda Molife,

Cancer Chemotherapy and Pharmacology

2009

34

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Alastair Greystoke, Sarah P. Blagden, Anne Thomas,

Annals of Oncology

2006

24

Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a “dietary-achievable” or “pharmacological” dose: what are the implications for anticancer activity?

Hong Cai, Edwina N. Scott, Robert G. Britton,

American Journal of Clinical Nutrition

2020

14

Page 1